Akorn ( AKRX) manufactures and markets a range of diagnostic and therapeutic ophthalmic pharmaceuticals, as well as niche hospital drugs and injectable pharmaceuticals. This stock is trading up 11% to $9.98 in recent trading, after it hit a 52-week high of $10.10 earlier today. Today's Range: $8.85-$10.10 52-Week Range: $4.37-$10.10 Volume: 3.1 million Three-Month Average Volume: 1.12 million Akron has a market cap of $946.41 million and an enterprise value of $815.25 million. The stock trades at a trailing price-to-earnings of 20.56 and a forward price-to-earnings of 29.38. Its estimated growth rate for this year is 61.10%, and for next year it's pegged at 17.20%. The current short interest as a percentage of the float for Akron is notable at 7.7%. This company reported record third-quarter earnings today on revenue of $36.6 million, a 69% increase from the same quarter last year. The company also raised its 2011 outlook to $130 million to $132 million. From a technical standpoint, this stock has triggered a major breakout today on high volume now that the stock has punched through some past overhead resistance at $9.50 a share. This move today is pushing AKRX to brand new all-time highs. As long as the stock can sustain a move and close above $9.50, then it should be setting up to trend significantly higher. I recently included Akron in a list of stocks under $10 setting up to trade higher.
Shares of Valeant Pharmaceuticals jumped following last night's report by The Wall Street Journal saying that the company rejected a joint takeover approach from Takeda Pharmaceuticals and TGP Capital.